HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
KYNB
Kyntra Bio, Inc.
There isn't enough reported data to score KYNB yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
KYNB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
KYNB's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
KYNB PE Valuation
KYNB has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
KYNB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect KYNB's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
KYNB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $45.20 | +$45.58 |
| Q1 2026 | $40.36 | +$42.86 |
| Q4 2025 | $45.37 | +$57.37 |
| Q3 2025 | $53.48 | +$83.98 |
| Q2 2025 | -$0.38 | +$42.12 |
| Q1 2025 | -$2.50 | +$58.50 |
| Q4 2024 | -$12.00 | +$61.00 |
| Q3 2024 | -$30.50 | +$46.00 |
KYNB has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 154% for KYNB.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
KYNB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $3.7M | +36% |
| Q2 2025 | $1.3M | -97% |
| Q1 2025 | $2.7M | -95% |
| Q3 2024 | $46.3M | +15% |
| Q2 2024 | $50.6M | +14% |
| Q1 2024 | $55.9M | +55% |
| Q4 2023 | $27.1M | -21% |
| Q3 2023 | $40.1M | +155% |
KYNB's revenue has slid since its 2021 peak: −$1M last quarter, down 154% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -370% | +175 points |
| Q4 2025 | -1058% | N/A |
| Q2 2025 | -894% | -873 points |
| Q1 2025 | -545% | -489 points |
| Q3 2024 | -36% | +122 points |
| Q2 2024 | -22% | +177 points |
| Q1 2024 | -56% | +155 points |
| Q4 2023 | -200% | -7.2 points |
KYNB's operating margin was −370% last quarter, down 333 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over KYNB on cash generation, producing positive trailing cash flow while its opponent burns cash.
KYNB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4M | -132% |
| Q1 2026 | -$13.9M | -614% |
| Q4 2025 | -$18.3M | +$12.3M |
| Q3 2025 | -$1.9M | +$6.6M |
| Q2 2025 | $12.7M | +$52.6M |
| Q1 2025 | $2.7M | +$62M |
| Q4 2024 | -$30.6M | -$12M |
| Q3 2024 | -$8.5M | +$76.8M |
KYNB has burned cash in almost every quarter: −$38M over the past year, against −$24M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over KYNB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
KYNB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1K shares |
| 1 year | +0.1% | +6K shares |
| 3 years | +3.6% | +139K shares |
| 5 years | +9.7% | +357K shares |
| Available history | +16% | +568K shares |
KYNB has 4M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $5,000 |
| Q4 2024 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
KYNB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2019 | -4.7x | Net Cash |
KYNB has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
KYNB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.1 | Oversold |
| Stochastic | 3.4 | Oversold |
KYNB's weekly RSI is 25 (oversold) and its Stochastic is 3 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
KYNB PE vs Healthcare Sector
| Metric | KYNB | Sector median | Relative |
|---|---|---|---|
| PE | 0.1x | 26x | 100% below |
| PE % | 0 | 29 | 29 pts below |
KYNB has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
KYNB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.09 | 29% below |
| 20 week MA | $6.52 | 45% below |
| 50 week MA | $7.17 | 50% below |
| 100 week MA | $8.50 | 58% below |
| 200 week MA | $70.4 | 95% below |
KYNB is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over KYNB on returns for 2026, with the stronger performance.
KYNB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,122.3 | $1,010.3 | -10% |
| 2021 | $1,010.3 | $384.8 | -62% |
| 2022 | $384.8 | $390.3 | +1.4% |
| 2023 | $390.3 | $22.2 | -94% |
| 2024 | $22.2 | $14.5 | -35% |
| 2025 | $14.5 | $8.90 | -39% |
| 2026 YTD | $8.90 | $3.59 | -60% |
KYNB has finished three years in a row lower, and it's down 60% so far in 2026.